Articles On Kazia Therapeutics (ASX:KZA)

Oncology-focused drug development company Kazia Therapeutics (ASX:KZA) has announced the publication of positive preclinical data for EVT801, a clinical-stage drug candidate currently in a clinical trial for multiple forms of cancer...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Small caps up 0.86% while global markets wait for US midterm election results  Aussies have hit a record 1 million side hustles as the cost of living rises ReNu Energy nabs $100m investment from superannuation fund for green hydrogen proj...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings lodgements. To save you the trouble of trudging through it all, we’ve wrapped up the highlights from some of the reports that caug...

ShareCafeASX increases slightly ahead of today’s rate rise: Aus shares 0.3% higher at noon by Peter Milios   Last week’s rally for US equities ground to a halt overnight ahead of this week’s Federal Reserve decision on interest rates, as te...

28 Oct 2022 - A snapshot of the stocks on the move featuring Kazia Therapeutics(ASX:KZA), Green Technology Metals (ASX:GT1) and Winsome Resources (ASX:WR1).

ShareCafeUS tech earnings weighing down Aus tech sector: ASX falls 0.62% at noon by Lauren Hayes   Disappointing earnings from major US tech companies, including Meta, Apple and Amazon, has caused the Information Technology sector on the AS...

ShareCafeStocks of the Hour: KZA, GT1, WR1                    Yesterday after close, Kazia Therapeutics (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announced the presentation of new data from an ongoing res...

Kazia Therapeutics’ (KZA) paxalisib brain cancer drug demonstrates positive efficacy signals against a range of preclinical models of metastatic melanomaThe study suggested substantial activity for paxalisib as a monotherapy and greater act...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Dual-listed brain cancer specialist Kazia Therapeutics is preparing for a possible launch of its drug paxalisib in the US market. The process of taking a drug from discovery to the commercial arena is extremely complex, with the clinical t...

ASX 200 drops load circa 1430 (AEST)  ends 0.4% lower Small caps index laughs openly in face of danger, gains 1% RBA hits us with another 50bps rate hike   The ASX 200 — not unlike the still, glassy ocean before a hurricane — was flat an...

Unlike the majority of biotech players, Kazia Therapeutics has emphasised diversity in its clinical trials, so as to look at the potential of its lead drug paxalisib in a range of different treatment areas. The company currently has eight c...

ShareCafeEvening Report: 8 August, 2022 by Paul Sanger   After falling early in the session, the ASX managed to close in the green. Lithium stocks led the way, following comments from Albemarle that the lithium supply will remain tight for...

08 Aug 2022 - A snapshot of the stocks on the move featuring Kazia Therapeutics (ASX:KZA), Mesoblast (ASX:MSB), BHP Group (ASX:BHP) and Oz Minerals (ASX:OZL).

ShareCafeLunch Report: 8 August, 2022 by Paul Sanger   On the ASX this week we kick off the earnings season with 17 major ASX 200 companies reporting, including Suncorp (ASX:SUN) (today and more on its proposed bank sale to the ANZ), Comput...

ShareCafeStocks of the Hour: 8 August, 2022                    Kazia Therapeutics Limited (ASX:KZA) an oncology-focused drug development company, is pleased to announce the presentation of promising new data from an ongoing phase 1 cl...

Acrux and Lumos are waiting for FDA’s approvals Paradigm will present Phase 2 results Neuren commences Phase 2 trials Acrux (ASX:ACR) says the FDA has accepted its application for a generic version of coldsore treatment, ‘Acyclovir Cream,...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

Kazia Therapeutics (KZA) presents “promising” new data from an ongoing phase I clinical trial of its paxalisib product for the treatment of brain metastases The trial treated nine patients with paxalisib in combination with radiotherapy, w...

Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) has presented promising new data from an ongoing phase one clinical trial of its lead drug paxalisib in combination with radiotherapy for the treatment of brain metastases. Inter...

The ASX 200 will open slightly lower on Monday US non-farm payrolls surprise on the upside, but Wall Street finishes mixed on Friday Ahead this week, earnings season starts for ASX blue chips Local shares are set to open lower today. At 8...

ShareCafeThe Week that Was – August 1-5, 2022 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so, h...

ShareCafeLunch Report: 5 August, 2022 by Tim McGowen   Gold stocks are stronger across the board as the price of gold reaches one month highs as the $US weakens and geopolitical tensions rise with China & Taiwan. The annual Diggers &amp...

ShareCafeGlobal Biotech Turnaround Looks to Be Underway Signs of life are emerging in the global biotech sector, after the longest and sharpest downturn in history that was so severe it left hundreds US companies trading below cash backing....

ShareCafeKazia: AGILE Hurdle Missed but Significant Value Remains Corporate Connect analyst Marc Sinatra has today released an updated research report for ASX-listed biotech company Kazia Therapeutics (ASX: KZA), now available for download...

The ASX 200 is up 0.6%, the XEC small caps index is down 0.8%  Tomorrow is RBA day, Wednesday is OPEC+ arvo We all should’ve bought into CBE last week, dammit    The local sharemarket is creeping quietly higher on Wednesday, with the reso...

In case you were wondering, it is the Kazia Therapeutics Ltd (ASX: KZA) share price that’s crashing heavily today. After opening at 35 cents for the day, shares in the oncology-focused drug development company are continuing to freefall....

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

SYDNEY, July 12, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the launch of its Scientific Advisory Board (SAB). The new SAB consists of fou...

Kazia Therapeutics (ASX: KZA) has launched a new scientific advisory board (SAB) consisting of “world-leading experts” in developing therapies for brain cancer. Sydney-based oncology-focused Kazia will lean on SAB’s guidance in progressing...

ShareCafeEvening Report: 6 July, 2022 by Melissa Darmawan   Australia’s trade surplus hit a record high in May, driven by higher prices of coal, while imports suggested consumer demand is strong as the country continues to open. The surplu...

ShareCafeLunch Report: 7 July, 2022 by Melissa Darmawan   Australian stocks have rebounded, helped by Chalice Mining’s latest discovery, which has helped to lift the material sector. Gains in consumer staples and discretionary stocks have o...

07 Jul 2022 - A snapshot of the stocks on the move, featuring Elsight (ASX:ELS), Kazia Therapeutics (ASX:KZA), and Chalice Mining (ASX:CHN).

Kazia Therapeutics’ (ASX: KZA) lead drug candidate paxalisib has been awarded rare paediatric disease designation (RPDD) for the treatment of a highly-aggressive childhood brain cancer known as atypical rhabdoid teratoid tumour (AT/RT). The...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

SYDNEY, July 6, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pedi...

Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) has made good progress in the first six months of the year with pipeline assets paxalisib and EVT801 despite a challenging equity market for biotech companies. A Phase I study of...

Kazia Therapeutics (ASX:KZA) has announced that the US FDA has granted Orphan Drug Designation to its paxalisib for the treatment of atypical rhabdoid/teratoid tumours.

SYDNEY, June 17, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan D...

The US FDA has awarded Kazia Therapeutics (KZA) Orphan Drug Designation (ODD) for its paxalisib drug to treat a rare type of childhood brain cancer The designation is for paxalisib to treat atypical rhabdoid/teratoid tumours which is a rar...

Highlights Kazia Therapeutics’ lead drug candidate, Paxalisib, secures ODD from the FDA for the treatment of a kind of brain cancer. Kazia will save over US$3 million in fees related to a future regulatory filing in atypical rhabdoid/t...

Kazia gets designation approval from US FDA Lumos signs contract to make at-home screening test product Trajan acquires US-based company, in trading halt Oncology company Kazia Therapeutics (ASX:KZA) says its lead drug paxalisib has been...

Kazia Therapeutics (ASX: KZA) has collared orphan drug designation (ODD) from the United States Food and Drug Administration for its lead candidate paxalisib in treating a rare and highly aggressive childhood brain cancer. The ODD is specif...

ShareCafeEvening Report: 14 June, 2022 by Paul Sanger   The Australian sharemarket has suffered its worst losses in over two years, obliterating $82bn of market capitalisation off the ASX 200. At the closing bell, the S&P/ASX 200 plunge...

“Positive data” is being presented regarding the activity of Kazia Therapeutics’ (ASX: KZA) lead drug paxalisib in two forms of childhood brain cancers. The company is presenting the data via two presentations this week at the 20th Internat...

14 Jun 2022 - A snapshot of the stocks on the move featuring Kazia Therapeutics (ASX:KZA), Westgold Resources (ASX:WGX) & Lake Resources (ASX:LKE).

Kazia Therapeutics (KZA) sees new data presented for its brain cancer drug, Paxalisib, highlighting its use in two forms of childhood brain cancer The data has been presented in two poster presentations at the International Symposium on Pe...